Sarah B. Noonberg's most recent trade in Neurogene Inc was a trade of 12,050 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on June 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neurogene Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 12,050 | 12,050 | - | - | Non-Qualified Stock Option (right to buy) | |
| Metagenomi Inc | Sarah B. Noonberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.75 per share. | 06 Jun 2025 | 5,239 | 109,135 | - | 1.7 | 9,168 | Common Stock |
| Metagenomi Inc | Sarah B. Noonberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 84,000 | 84,000 | - | - | Stock Option (Right to Buy) | |
| Metagenomi Inc | Sarah B. Noonberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 14,000 | 114,374 | - | 0 | Common Stock | |
| Marinus Pharmaceuticals Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 10,450 | 10,450 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 2,300 | 14,100 (0%) | 0% | 0 | Common Stock | |
| Neurogene Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 7,700 | 7,700 | - | - | Stock Option (Right to Buy) | |
| Metagenomi Inc | Sarah B. Noonberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 242,875 | 242,875 | - | - | Stock Option (Right to Buy) | |
| Metagenomi Inc | Sarah B. Noonberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 57,763 | 100,374 | - | 0 | Common Stock | |
| Marinus Pharmaceuticals Inc | Sarah Noonberg B. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 20,900 | 20,900 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 4,600 | 11,800 (0%) | 0% | 0 | Common Stock | |
| Neurogene Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 15,400 | 15,400 | - | - | Stock Option (Right to Buy) | |
| Neoleukin Therapeutics Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2023 | 32,400 | 32,400 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2023 | 7,200 | 7,200 (0%) | 0% | 0 | Common Stock | |
| Protagonist Therapeutics Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Neoleukin Therapeutics Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Protagonist Therapeutics Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 18,000 | 18,000 | - | - | Stock Option (right to buy) | |
| Neoleukin Therapeutics Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) |